During the past decade, Oklahoma Center For Arthritis Therapy & Research conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 12 clinical trials were completed, i.e. on average, 92.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma Center For Arthritis Therapy & Research" #1 sponsor was "Human Genome Sciences Inc." with 5 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "EMD Serono" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Center For Arthritis Therapy & Research" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "GlaxoSmithKline" with 2 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Center For Arthritis Therapy & Research" are "Systemic Lupus Erythematosus" (8 trials), "Rheumatoid Arthritis" (7 trials), "Lupus Erythematosus, Systemic" (5 trials), "Arthritis, Rheumatoid" (1 trials) and "Chronic Gout" (1 trials). Many other conditions were trialed in "Oklahoma Center For Arthritis Therapy & Research" in a lesser frequency.

Most popular intervention types in "Oklahoma Center For Arthritis Therapy & Research" are "Drug" (21 trials), "Biological" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Baricitinib" (4 trials), "Belimumab 1 mg/kg" (3 trials), "Belimumab 10 mg/kg" (3 trials) and "Atacicept 150 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Center For Arthritis Therapy & Research" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Oklahoma Center For Arthritis Therapy & Research". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Oklahoma Center For Arthritis Therapy & Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Center For Arthritis Therapy & Research, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".